Compare BCBP & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCBP | SLGL |
|---|---|---|
| Founded | 2000 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.8M | 117.8M |
| IPO Year | N/A | 2018 |
| Metric | BCBP | SLGL |
|---|---|---|
| Price | $8.38 | $42.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $9.25 | ★ $50.00 |
| AVG Volume (30 Days) | ★ 87.8K | 15.3K |
| Earning Date | 01-27-2026 | 11-20-2025 |
| Dividend Yield | ★ 7.63% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $64,592,000.00 | $18,970,000.00 |
| Revenue This Year | $23.06 | $121.82 |
| Revenue Next Year | $3.55 | N/A |
| P/E Ratio | $168.57 | ★ N/A |
| Revenue Growth | N/A | ★ 62.04 |
| 52 Week Low | $7.41 | $4.02 |
| 52 Week High | $13.17 | $52.26 |
| Indicator | BCBP | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 62.80 | 57.44 |
| Support Level | $7.85 | $38.30 |
| Resistance Level | $8.50 | $44.43 |
| Average True Range (ATR) | 0.16 | 3.59 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 82.49 | 68.45 |
BCB Bancorp Inc is a bank holding company. The company offers loans, including commercial and multi-family real estate loans, home equity loans, construction loans, consumer loans, and commercial business loans; FDIC-insured deposit products, such as savings and club accounts, interest and non-interest bearing demand accounts, money market accounts, certificates of deposit and individual retirement accounts, and retail and commercial banking services, including wire transfers, money orders, safe deposit boxes, a night depository, debit cards, online banking, gift cards, fraud detection and automated teller services.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.